Nexgenrx Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.97 Cr
- Paid Up Capital ₹ 1.97 Cr
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.89 Cr
- Revenue Growth 1347.70%
- Profit Growth 117.50%
- Ebitda 345.21%
- Net Worth 32.44%
- Total Assets 7.92%
About Nexgenrx Pharmaceuticals
Nexgenrx Pharmaceuticals Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 June 2016 (Eight years and seven months 18 days old ). Its registered office is in New Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.97 Cr and a paid-up capital of Rs 1.97 Cr.
The company currently has active open charges totaling ₹3.89 Cr.
Ritesh Srivastava, Mohammad Hasan, Pankaj Shrivastwa, and One other member serve as directors at the Company.
Company Details
-
Location
New Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U36994DL2016PTC302167
-
Company No.
302167
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Jun 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Nexgenrx Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritesh Srivastava
|
Director | 27-Jun-2016 | Current |
|
Mohammad Hasan
|
Director | 27-Jun-2016 | Current |
|
Pankaj Shrivastwa
|
Additional Director | 11-Jul-2019 | Current |
|
Ram Jha
|
Additional Director | 11-Jul-2019 | Current |
Financial Performance of Nexgenrx Pharmaceuticals.
Nexgenrx Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1347.7% increase. The company also saw a substantial improvement in profitability, with a 117.5% increase in profit. The company's net worth Soared by an impressive increase of 32.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexgenrx Pharmaceuticals?
In 2023, Nexgenrx Pharmaceuticals had a public holding of 67.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nexgen Rx Lifesciences Private LimitedMohammad Hasan is a mutual person
Charges (Loans)
₹3.89 Cr
₹0
Charges Breakdown by Lending Institutions
- Sidbi : 3.89 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Mar 2024 | Sidbi | ₹1.36 Cr | Open |
| 28 Dec 2021 | Sidbi | ₹5.28 M | Open |
| 18 Nov 2020 | Sidbi | ₹2.00 Cr | Open |
How Many Employees Work at Nexgenrx Pharmaceuticals?
Nexgenrx Pharmaceuticals has a workforce of 52 employees as of Apr 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexgenrx Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexgenrx Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
